Nomura analyzed MedPlus's financial performance and maintained a Buy rating despite weak performance.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura analyzed MedPlus's financial performance and maintained a Buy rating despite weak performance.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Nomura reaffirmed its 'Buy' rating and target price for Lupin Limited.
- Nomura upgraded the stock rating for Toto Ltd. on September 4, 2026.
- Nomura retained a buy rating, Morgan Stanley retained equal-weight, and CLSA downgraded Godrej Consumer Products stock.
- Nomura initiated coverage with a 'Reduce' rating on several e-commerce companies, including Meesho, Amazon, Swiggy, and Flipkart.
- Nomura provided market analysis and rating on Mahindra & Mahindra Ltd. on August 17, 2026.